Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue

GOTHENBURG, Sweden, Sept. 25, 2020 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces effects of VP01 on idiopathic pulmonary fibrosis (IPF)......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Friday, 25 September

Share |